Skip to content
Search

Latest Stories

Couple sells Greenwich pharmacy to first-time buyer

Couple sells Greenwich pharmacy to first-time buyer

The high-dispensing pharmacy attracted multiple offers resulting in a sale in excess of the original marketing price   

Specialist Pharmacy Brokers Hutchings Consultants have revealed that they successfully completed the sale of Totty Pharmacy, which is situated in an affluent suburb of Greenwich, London.


Previously owned by Akshay Patel and his wife, who assumed the primary pharmacist role, the pharmacy was highly profitable, dispensing an average of 5,500 items per month, and in superb condition having recently received a full refit.

The couple sold their pharmacy to a first-time buyer, named Samson Akere, for an undisclosed price.

The brokers, however, said Totty Pharmacy attracted multiple offers from both first-time buyers and existing London owners, resulting in a sale in “excess of the original marketing price.”

The Patels, who were regarded very highly in their local community, decided to sell the business to look for a more flexible career so that they can spend more time with their children.

Akshay said: “The time had finally come for a change in career, one that allowed us to spend more time with our children. We decided to sell our community pharmacy, making way for a younger generation with drive to grow the business.”

About choosing Hutchings for the sale process, he said they became aware of a very successful sale the brokers handled for a pharmacy around the corner, and that they were confident about their “ability and knowledge of the London area.”

The buyer, Akere was keen to get on the pharmacy owning ladder, and had been looking for a while, before he saw the potential of Totty Pharmacy, given its location, community standing, and room for growth.

Now that the sale is complete, he is excited to develop the business to its full potential.

“My focus is on maintaining and enhancing its good reputation among existing customers while welcoming new ones with top-notch service,” the new owner said.

Sharing his experience with Hutchings, he said: “I have dealt with other brokers in the past… Hutchings stand out for their exceptional speed and efficiency in handling the transaction.”

Matteo Mazza, pharmacy consultant from Hutchings who handled the sale, said that the transaction was efficiently handled by all parties involved, leading to another successful London pharmacy sale.

The pairing of buyer and seller is something that he found especially interesting.

“The Patels were hugely community focused and were keen to find someone to carry their work forward. Samson, a first-time buyer, who was eager to do exactly that while also injecting a new lease of energy into the business, was exactly what they were looking for,” Mazza added.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less